We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
Notice for nivolumab (Bristol-Myers Squibb Australia Pty Ltd)
Active ingredients
nivolumab
Date of review outcome
Lapse date
Type
Priority review
Indication
For the adjuvant treatment of Stage III/IV melanoma in patients who have undergone complete resection.
Registration date